Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia
Journal of Medical Virology · 2025-02 · 97 (2)
DOI: 10.1002/jmv.70235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 13.02.2025. Verfasst von Eric Kalo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Blacktown Clinical School and Research Centre, School of Medicine, Western Sydney University, Blacktown, New South Wales, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, COVID-19 Drug Treatment, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Laboratory‐based findings suggest that Sotrovimab is significantly less effective against emerging CARS‐CoV‐2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high‐risk subgroups of patients during the SARS‐CoV‐2 Delta and Omicron waves in Western Sydney, Australia ( n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36–2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blacktown Clinical School and Research Centre, School of Medicine, Western Sydney University, Blacktown, New South Wales, Australia.
- Integrated and Community Health, Western Sydney Local Health District, Blacktown Hospital, Blacktown, New South Wales, Australia.
- Blacktown Hospital, Western Sydney Local Health District, Blacktown, New South Wales, Australia.
- Storr Liver Centre, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
- Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales, Australia.
- New South Wales Health Pathology, ICPMR-Westmead, Westmead, New South Wales, Australia.
ORCID-Profile: Scott Read
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Kalo, E., Basyouni, Z., Katz, G. M., Karkvandi, V., Watson, L., Crowther, H., Read, S., O'Sullivan, M. V. N., Ellis, J., Medlin, J., & Ahlenstiel, G. (2025). Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70235
Vancouver
Kalo E, Basyouni Z, Katz GM, Karkvandi V, Watson L, Crowther H, et al. Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70235
BibTeX
@article{Kalo2025,
author = {Kalo, Eric and Basyouni, Ziad and Katz, Gideon Meyerowitz and Karkvandi, Vahid and Watson, Leanne and Crowther, Helen and Read, Scott and O'Sullivan, Matthew V N and Ellis, Jasmin and Medlin, Joanne and Ahlenstiel, Golo},
title = {Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia},
journal = {Journal of Medical Virology},
year = {2025},
volume = {97},
number = {2},
doi = {10.1002/jmv.70235}
}
EUVIMED